Short and mid-term outcomes and functional results in metal-on-metal hip resurfacing arthroplasty at 5 years follow-up: the Spanish experience

Olga S. Pérez-Moro 1*, Marcos E. Fernández-Cuadros 1, Inmaculada Neira-Borrajo 2, Eduvigis Aranda-Izquierdo 2, María J. Albaladejo-Florin 1 and Rafael Llopis-Miró 2

Abstract

Background: Hip resurfacing arthroplasty (HRA) and in particular, Birmingham hip resurfacing (BHR), is commonly employed as an alternative to total hip arthroplasty (THA) in young patients, as it allows for preservation of femoral bone stock and resumption of physical activity. The aim of our study was to investigate 5-year survival and functional outcomes of BHR arthroplasty in young Spanish osteoarthritis (OA) patients.

Methods: This is an observational, prospective, cohort study of patients who underwent BHR between June 2005 and December 2009 at a Spanish public hospital with a minimum follow-up of 5 years. All surgeries were performed by a single surgeon (RLM). Survival was analyzed using the Kaplan-Meier method. Functional outcomes and return to work and physical activities were also assessed.

Results: Five-year survival rate of the prosthesis was 95.74% (95% CI: 95.77–98.07), and estimated 10-year survival was 92.92% (95% CI: 85.07–96.72). Harris hip score significantly increased from 41.13 to 97.63 (p < 0.001) at 5-year follow-up. Average time for returning to work and sporting activities was 3.89 (SD: 2.39) and 3.47 (SD: 1.18) months respectively. Failure occurred in 14 patients, 8 of whom experienced femoral neck fractures.

Conclusions: Our data support the short and mid-term efficacy of BHR arthroplasty in young OA patients, indicating good implant survival, improvement in patients’ functionality and a swift return to work and physical activities after surgery.

Keywords: Osteoarthritis, Birmingham hip resurfacing, Hip prosthesis, Survival analysis

Background

Total hip arthroplasty (THA) is regarded as an effective alternative in the treatment of patients with hip osteoarthritis (OA) [1]. Despite being a successful procedure, several studies have indicated that THA may not be the best option in younger patients, due to the higher rate of aseptic loosening and subsequent increased risk of revision surgery observed in this population [1–4]. It has been hypothesized that the higher functional demands and intensity of physical activity, leading to higher wear and mobilization of the prosthesis, may be responsible for the lower success of this procedure in younger patients [5].

Based on this, in the late 70s (1979), hip resurfacing arthroplasty (HRA) attracted surgeons’ attention as a bone conserving alternative to THA for the treatment of young patients with OA [3].

In comparison with THA, HRA does not involve femoral head removal, allowing for the preservation of the proximal femoral bone stock while providing a functional range of motion (ROM), restoring proprioception, hip joint biomechanics and hip stability [6–8]. The first generation of HRA prostheses was, however, associated with a high rate of wear, aseptic loosening (often secondary to osteolysis) and complications such as femoral neck fracture [7–9].
Changes in the design and biomaterials employed, led to the development of a second generation of resurfacing prostheses [10]. This, along with improvements in the surgical technique, had a direct impact on implant wear, endurance and clinical outcomes [10].

A wide variety of bearing materials are currently available for HRA; bearing couples may consist of metal-on-metal, metal-on-polyethylene, ceramic-on-ceramic or ceramic-on-polyethylene systems. The most commonly used bearing couple is the Birmingham Hip Resurfacing (BHR) system, a metal-on-metal (MoM) prosthesis whose components are produced from a highly polished cobalt-chromium alloy (2 μm surface roughness) which results in low wear and friction rates.

This prosthesis has been associated with several advantages. In particular, the use of BHR prostheses with larger diameter heads (36-54 mm) has been shown to reduce the risk of hip dislocation and to provide a greater ROM compared to classic THA [11]. Additionally, BHR has been shown to facilitate femoral replacement and conversion to THA, if needed [11]. On the other hand, the lack of modularity of the implant, which may limit the correction of limb asymmetry, the potential risk of early fractures of the femoral neck (0.4%), adverse local tissue reaction (ALTR) to metal debris or pseudotumor formation represent potential sources of concern with regard to these implants [10, 12–16]. In addition, the long learning curve and the technical complexity of the surgical procedure still limit the use of BHR among surgeons [10, 14]. Despite this, reports showing high short to mid-term survival rates of this prosthesis [17, 18] have rekindled interest in the use of BHR for the treatment of OA in patients with high functional demands.

In light of the above, the objective of this study was to investigate short and mid-term survival of BHR prostheses as well as functional outcomes, in Spanish patients undergoing HRA at a Spanish public hospital.

**Methods**

**Study design**
A prospective observational study was conducted in 145 consecutive patients who received metal-on-metal BHR arthroplasties between June 2005 and December 2009 at a Spanish public hospital (Hospital Universitario Santa Cristina, Madrid). The study was approved by the Clinical Research Ethics Committee of La Princesa University Teaching Hospital and was performed in accordance with the guidelines of the Helsinki Declaration. All patients provided written informed consent preoperatively. Patients were followed-up for a minimum of 5 years, until October 2015.

**Inclusion/exclusion criteria**
The following inclusion criteria were used: women ≤60 years and men ≤65 years presenting with either pain secondary to OA, avascular necrosis (AVN) or developmental hip dysplasia; inability to perform activities of daily living (ADL); asymmetry of the limbs < 3 cm; absence of kidney disease and good bone quality. Women of reproductive age, as well as patients with one or more of the following conditions were excluded from the study: osteoporosis, active rheumatoid arthritis, ankylosing spondylitis, alcoholism, steroidal treatment, renal insufficiency and allergy to metals (Co and Cr).

**Surgical procedure**
After a thorough explanation of the advantages and disadvantages of the technique and the differences with classical THA, all of the patients provided informed consent before undergoing BHR surgery. All surgeries were performed with a BHR system (Smith and Nephew) by a single surgeon (R. Llopis-Miró). A modified posterior lateral approach was used in order to preserve the blood supply to the femoral head [19]. In patients in which a posterior approach was deemed inappropriate, an anterior approach was used. All patients received epidural anesthesia. Patients received 2 g of cefazolin as antibiotic prophylaxis before surgery and then every 8 h during the first day. Enoxaparin 40 mg (daily for up to 30 days) and physical therapy (compressive socks plus plantar air pumps) as deep venous thrombosis (DVT) prophylaxis immediately after surgery.

In accordance with the fast track protocol implemented in the hospital since 2005, on the first day after surgery all patients underwent drainage and were mobilized (sitting and standing) for a few seconds. Over the next few days, patients were asked to walk with a cane, learn to transfer (from bed to chair and back again), exercise quadriceps and hamstring muscles, climb stairs and learn to wash and dress unassisted. In patients with signs of either inflammation or bone/tissue damage at follow-up, a biochemical (monitoring of cobalt-chromium ion levels) and clinical evaluation was conducted, to rule out the presence of any ALTR and/or pseudotumors formation.

**Main variables and outcomes**
Demographic variables analyzed included age, sex, weight, height, body mass index (BMI), ROM and asymmetry of the limbs. Surgical variables included anesthetic type, size of the head and acetabulum of the prosthesis, surgical approach and need for blood transfusion. Radiological variables included femoral offset, acetabular and cervical-diaphyseal angles (Fig. 1). Presence of radio lucencies and neck thinning was also evaluated by radiographic examination.

The primary outcome was the survival of the BHR prosthesis at a minimum follow-up of 5 years (a 10-year-survival rate was also estimated based on the proportion of patients who had undergone a follow-up
visit at 10-years). Other variables included length of stay (LOS), need to perform outdoor rehabilitation, and time needed to return to work and to sport activities. Functional outcomes included Oxford hip score (OHS) and Harris hip score (HHS) pre- and post-surgery [20, 21]. Variables for which 5 year follow up data were not available, were analyzed at the maximum follow-up period available.

**Statistical analysis**

For quantitative variables, mean, standard deviation (SD), median, minimum and maximum were calculated. For qualitative variables, absolute and relative frequencies were determined. Confidence interval was set at 95% ($p < 0.05$). McNemar, U-Mann Whitney and Wilcoxon tests were used to compare qualitative and quantitative variables where appropriate. Measurements of the same variable from the same sample at different times were compared using the McNemar and the non-parametric Wilcoxon test for qualitative and quantitative variables, respectively. To compare quantitative variables in two different groups of independent patients, the Mann-Whitney U test was used.

Survival of the BHR prosthesis was defined as the time from implantation to the occurrence of any complication during the follow-up period. The survival analysis was carried out using the Kaplan-Meier Method. Implant survival for each patient was computed as the difference between date of operation and date of revision surgery. The Cox-regression method was used to identify predictive factors of prosthesis survival; age, sex, BMI and practice of sports were included in the regression as independent variables.

All statistical analyses were carried out using the STATA® (version 14) statistical package. The level of significance was established at 95% ($p < 0.05$).

**Results**

**Demographic, clinical and surgical variables**

Over the study period, 145 out of 230 patients completed the minimum 5-year follow-up and were included in the analysis (Table 1). Of these, 117 (80.69%) were male. The mean age of the patients was 49.5 years (SD: 9.67), with a mean BMI of 26.8 kg/m$^2$ (SD: 3.54). The most common pre-operative diagnosis was hip OA, accounting for 60% of the surgeries ($N = 87$). With respect to laterality, 53.1% of the surgeries ($n = 77$) involved the right side. Nearly all of the procedures ($n = 140; 96.55$%) were performed using a posterior lateral approach, while an anterior lateral approach was employed for the remaining prostheses ($n = 5, 3.45$%). Mean femoral head size was 50 and 42 mm for male and female patients, respectively. Mean acetabular size was 56 mm for men and 48 mm for women. The number of patients with limb asymmetry significantly decreased from 90 (60%) to 64 (39.9%, $p < 0.01$) after the procedure. Similarly, mean
asymmetry showed a significant reduction, going from 0.86 cm (SD: 0.44) to 0.55 cm (SD: 0.38; \( p = 0.001 \)) after the surgery (Table 2). Additionally, hip ROM significantly improved, increasing from 87.90° before surgery to 98.56° 1 year after surgery (\( p < 0.001 \)) (Table 3). At radiological evaluation, mean femoral offset was 2.99 mm (SD: 0.57), mean cervical-diaphyseal angle was 139.28° (SD: 5.6) while mean acetabular angle was 40.3° (SD: 7.27) (Table 1). Only 9 patients (6.21%) required a blood transfusion after the surgery (Table 1).

**Outcome variables**

Prosthesis survival rate, defined as the time from surgery to the occurrence of any complication, was estimated at 95.74% (CI 95.77–98.07) at 5-year follow-up. In patients for whom 10-year follow-up data were available, the 10-year survival rate was estimated at 92.92% (CI 85.07–96.72) (Fig. 2). When analyzing possible predictors of prosthesis failure, we found that higher BMI was associated with a significantly higher risk of failure (HR: 1.37; \( p = 0.008 \)). Conversely, a significantly lower risk of prosthesis failure was observed in patients who were active in sports compared to patients who were not (HR: 0.13; \( p = 0.069 \)). With regard to gender and age, none of these factors had a significant effect on prosthesis survival.

Mean LOS was 3.96 days (SD: 0.8), with a mean LOS of inpatient rehabilitation of 3.52 days (SD: 0.7). The average time for returning to physical activity was 3.47 months (SD: 1.8) while average time to return to work was 3.89 months (SD: 2.39) after surgery (Table 1).

**Functional outcomes**

Average Harris Hip Score (HHS) increased from 41.13 (SD: 9.98) preoperatively to 78.66 (SD: 8.21, \( p < 0.001 \)) 1 month after surgery and progressively improved up to 97.63 (SD: 5.69, \( p < 0.001 \)) at 5-year follow-up (Table 4, Fig. 3). Similarly, OHS scores indicated that functional capacity significantly improved in the first month after surgery, decreasing from 46.74 (SD: 5.47) to 17.32 (SD: 7.15; \( p < 0.001 \)). At 2 years of follow-up, the average OHS score was 11.38 (SD: 3.93), indicating a further improvement in functional capacity (Table 5, Fig. 4).

**Complications**

During the follow up period, there were 8 fractures (5.52%), 2 collapses of the femoral head (neck thinning) (1.38%), 2 revision surgeries secondary to pain (1.38%), and a psoas tendinitis (0.69%) (Table 6, Fig. 5). Finally, evidence of radiolucency indicative of osteolysis was described in one patient (0.69%) (Fig. 6). No patients showed ALTR or pseudotumor formation during follow-up.

All fractures occurred between 2 and 3 weeks after surgery and none of them was secondary to a fall. At

---

**Table 1** Baseline characteristics of the study cohort and surgical variables analyzed. (Table should be included in the “Demographic, clinical and surgical variables” paragraph, within Results section)

| Variables                      | Pre-surgical | Surgical |
|--------------------------------|--------------|----------|
| Age (year; SD)                 | 49.52 (9.67) |          |
| Male (n; %)                    | 117 (80.69)  |          |
| BMI (kg/m²; SD)                | 26.8 (3.54)  |          |
| Hip OA (n; %)                  |              |          |
| Developmental hip dysplasia (n; %) | 43 (29.65) |          |
| Aseptic bone necrosis (n; %)   | 12 (8.28)    |          |
| Legg-Calvé-Perthes disease (n; %) | 2 (1.38)     |          |
| Traumatic hip dislocation (n; %) | 1 (0.69)   |          |
| Right sided (n; %)             | 77 (53.1)    |          |
| Left sided (n; %)              | 68 (46.9)    |          |
| Posterior lateral approach (n; %) | 140 (96.55) |          |
| Anterior lateral approach (n; %) | 5 (3.45)    |          |
| Male femoral size (mm; SD)     | 50           |          |
| Female femoral size (mm; SD)   | 42           |          |
| Male acetabular size (mm; SD)  | 56           |          |
| Female acetabular size (mm; SD) | 48         |          |
| Global femoral size (mm; SD)   | 47.49 (3.57) |          |
| Global acetabular size (mm; SD) | 53.52 (3.52) |        |
| Cervical-diaphyseal angle (°; SD) | 139.28 (5.69) |    |
| Acetabular angle (°; SD)       | 40.3 (7.27)  |          |
| Femoral off-set (cm; SD)       | 2.99 (0.57)  |          |
| Need for blood transfusion (n; %) | 9 (6.21)     |          |
| Post-surgical                  |              |          |
| Length of stay (days; SD)      | 3.96 (0.8)   |          |
| Inpatient Rehabilitation (days; SD) | 3.52 (0.7) |          |
| Return to playing sports (months; SD) | 3.47 (1.8) |         |
| Return to work (months; SD)    | 3.89 (2.39)  |          |

**Table 2** Limb asymmetry pre-surgery and 3-months post-surgery

| Asymmetry                    | Mean | SD  | CI 95% | Median | Min | Max | n  | Missing data | p-value |
|------------------------------|------|-----|--------|--------|-----|-----|----|--------------|---------|
| Pre-surgery                  | 0.86 | 0.44| 0.77–0.95 | 0.8    | 0.5 | 2.5 | 90 | 55           | 0.001   |
| 3-months post-surgery (cm)   | 0.55 | 0.38| 0.46–0.65 | 0.5    | 0   | 2   | 64 | 81           | Ref.    |

The \( p \)-value corresponds to a comparison between the asymmetry values pre-surgery and post-surgery using the Wilcoxon Test

SD standard deviation, CI confidence interval
Table 3 Flexion range of motion (ROM) pre-surgery and post-surgery

| Flexion          | Mean  | SD   | CI 95%       | Median | Min | Max | n  | Missing data | p-value |
|------------------|-------|------|--------------|--------|-----|-----|----|--------------|---------|
| Pre-surgery      | 87.90 | 8.09 | 86.57–89.23  | 90     | 40  | 110 | 145| 0            |         |
| 1-month post-surgery | 86.36 | 9.25 | 84.83–87.89  | 90     | 0   | 105 | 143| 2            | 0.1694  |
| 3-months post-surgery | 91.92 | 9.60 | 90.33–93.51  | 90     | 0   | 110 | 143| 2            | < 0.001 |
| 6-months post-surgery | 96.39 | 10.13| 94.72–98.07  | 95     | 0   | 115 | 143| 2            | < 0.001 |
| 1-year post-surgery | 98.56 | 10.17| 96.88–100.24 | 100    | 0   | 115 | 143| 2            | < 0.001 |

The p-value corresponds to a comparison between the flexion ROM values pre-surgery and different post-surgery evaluations using the Wilcoxon Test.

SD standard deviation, CI confidence interval

Table 4 Harris Hip Score pre-surgery and post-surgery

| Harris Hip Score | Mean  | SD   | CI 95%       | Median | Min | Max | n  | Missing data | p-value |
|------------------|-------|------|--------------|--------|-----|-----|----|--------------|---------|
| Pre-surgery      | 41.11 | 9.83 | 39.50–42.72  | 42     | 18  | 60  | 145| 0            |         |
| 1-month post-surgery | 78.66 | 8.21 | 77.31–80.02  | 80     | 50  | 95  | 143| 2            | < 0.001 |
| 3-months post-surgery | 88.99 | 6.33 | 87.94–90.03  | 90     | 60  | 100 | 143| 2            | < 0.001 |
| 6-months post-surgery | 88.99 | 6.33 | 87.94–90.03  | 90     | 60  | 100 | 143| 2            | < 0.001 |
| 1-year post-surgery | 96.77 | 3.68 | 96.16–97.38  | 98     | 80  | 100 | 142| 3            | < 0.001 |
| 2-years post-surgery | 97.18 | 3.37 | 96.61–97.74  | 99     | 80  | 100 | 137| 8            | < 0.001 |
| 3-years post-surgery | 97.55 | 2.42 | 97.15–97.96  | 98     | 90  | 100 | 137| 8            | < 0.001 |
| 4-years post-surgery | 97.28 | 3.05 | 96.76–97.80  | 98     | 80  | 100 | 134| 11           | < 0.001 |
| 5-years post-surgery | 97.63 | 2.58 | 97.19–98.07  | 99     | 90  | 100 | 134| 11           | < 0.001 |

The p-value corresponds to a comparison between the Harris Hip Scores pre-surgery and post-surgery using the Wilcoxon Test.

SD standard deviation, CI confidence interval

Fig. 2 BHR arthroplasty survival evaluated by Kaplan-Meier Method (0–10 years)
revision surgery, the femoral component was replaced with a metal-on-metal Synergy stem with a large femoral head (Smith & Nephew). The psoas tendonitis resolved after steroidal infiltration. One of the 8 patients reporting fractures suffered from wound infection secondary to *Enterobacter cloacae* that resolved with a specific antibiotic treatment. No vascular or nerve lesions, dislocation or heterotopic ossification were reported in the study cohort.

**Discussion**

To the best of our knowledge, this is the first study to report short- to mid-term clinical outcomes of HRA using BHR performed by a single surgeon in a Spanish Public Hospital. Our findings indicate that BHR may be an effective treatment option for young patients with OA, with a 5-year survival rate of 95.74% and a predicted 10-year survival rate of 92.92%. The relevance of this report lies in that, although limited to a single center, it provides information regarding BHR’s effectiveness in routine clinical practice in Spain, allowing for benchmarking both nationally and internationally, thus laying the basis for further improvement of the quality of care for patients with OA in our setting. The efficacy of BHR in terms of prosthesis survival have been previously evaluated in several other studies in different settings [17, 22, 23]. In particular, in a study conducted in England in young patients (mean age 52.1 years) with OA, Treacy and McBryde reported 5-year and 6.1-year survival rates of 98 and 93.2%, respectively [22]. The similarities between these results and the one reported in the present study may be due to the similar characteristics of the studies’ cohorts (i.e. young active patients) and the surgical approach chosen. In a longer follow-up study conducted in a similar population, Murray et al. found that survival of BHR prostheses was strongly influenced by gender, approaching a 95% survival rate at 10 years in male patients vs. only 74% in female patients.

**Table 5** Evaluation of Oxford Hip Score pre-surgery and post-surgery

| Oxford Hip Score | Mean  | SD    | CI 95%         | Median | Min | Max | n | Missing data | p-value |
|------------------|-------|-------|----------------|--------|-----|-----|---|--------------|---------|
| Pre-surgery      | 46.74 | 5.37  | 45.86–47.62    | 47     | 32  | 60  | 145| 0            | < 0.001 |
| 3-month post-surgery | 17.32 | 7.15  | 16.14–18.50    | 15     | 10  | 57  | 143| 2            | < 0.001 |
| 6-months post-surgery | 12.83 | 2.91  | 12.34–13.31    | 12     | 10  | 27  | 143| 2            | < 0.001 |
| 1-year post-surgery | 11.41 | 2.49  | 11.00–11.82    | 10     | 10  | 30  | 143| 2            | < 0.001 |
| 2-years post-surgery | 11.38 | 3.93  | 10.70–12.06    | 10     | 10  | 45  | 143| 2            | < 0.001 |

The p-value corresponds to a comparison between the Oxford Hip Scores pre-surgery and post-surgery using the Wilcoxon Test.

SD: standard deviation, CI: confidence interval.
Data from Daniel et al. also support the mid- to long-term efficacy of BHR arthroplasty in patients with high functional demands, with 10-year and 15-year survival rates of 97.4 and 95.8%, respectively [24]. Similarly to what was observed by Treacy et al., a significantly lower survival rate was observed in women (91.5%) compared to male patients (98.0%) at 15 years follow-up [24]. In contrast, we observed no significant impact of female gender on prosthesis survival. This may be explained by the fact that, given the smaller sample size and higher proportion of women in the study cohort, this study may not have been powered enough to detect such differences.

It has been proposed that BHR prosthesis may allow the resumption of an active lifestyle, addressing the expectations of young, active patients with OA who would like to return to a normal level of physical activity after the surgery. Despite this, only a few studies have investigated return to sporting activities following BHR arthroplasty [25]. In our study, we observed a mean return to physical activity after approximately 3.5 months, demonstrating that young patients treated with BHR may resume preoperative sporting activity soon after surgery. These results are in line with those reported by Sandiford et al. [25], who observed that young patients with OA (mean age 55.8 years) who underwent BHR arthroplasty were able to return to sports by 3 months and perform the same number of activities at preoperative intensity.

Given the encouraging results achieved through BHR arthroplasty, mainly due to advances in the implant design and surgical approaches as well as to a better understanding of hip biomechanics and implant placement, the popularity of BHR has increased over the last decade [25]. Nevertheless, despite its many theoretical advantages (i.e., bone stock preservation, ease of revision surgery and reduced stress transfer due to a large femoral head), the use of BHR has been associated with complications such as avascular necrosis (AVN), periprosthetic femoral neck fracture and pseudotumor formation [15, 16, 26, 27]. Periprosthetic femoral neck fracture generally occurs within the first 3 months after surgery and reports from the literature suggest a prevalence of approximately 1 to 4% in patients who receive a BHR prosthesis [26–29]. It is noteworthy to mention that Quesada et al. have reported that a high rate of periprosthetic fracture is generally observed in the first 50 hip surgeries \((n = 11; 22\% )\) of a surgeon’s learning curve, and progressively diminishes to one fracture (2%) in the next 50 surgeries and no fractures at all in the next 200 surgeries [30]. In our study, the incidence of femoral neck fractures was slightly higher than the one reported in the literature, with 5.52% of the study patients reporting this

![Fig. 4 Oxford Hip Scores at 0–2 years follow-up](image)

**Table 6** Complications observed during the follow-up period

| Complication             | n (%) |
|--------------------------|-------|
| Fractures (n; %)         | 8 (5.52) |
| Collapses (neck thinning) (n; %) | 2 (1.38) |
| Revision surgery (n; %)  | 2 (1.38) |
| Osteolysis (n; %)        | 1 (0.69) |
| Psoas Tendinitis (n; %)  | 1 (0.69) |
complication in the follow up period. This may be partly explained by the high average BMI of the study population (26.8 kg/m²). Indeed, elevated BMI has been described as a potential risk factor for periprosthetic femoral neck fracture [31]. Other factors include poor bone stock quality, improper surgical technique, excessive varus of the implants, neck femoral notch, necrosis of sub-capital head and femoral head cysts > 2 cm [31, 32].

AVN of the remaining proximal femur has also been reported to predispose to periprosthetic femoral neck fracture [14]. Reaming of the femoral neck and avascular injury due to the surgical approach have been proposed as possible mechanisms for AVN after resurfacing [33–37]. In our series, two AVN of the femoral head (1.38%) were reported over the 5-year follow-up period. Although the true incidence of AVN is not known [36], our results are close to those reported by Daniel et al., and De Smet et al., who observed 0.2 and 0.4% rates of AVN, respectively [17, 38]. Pseudotumor formation is also recognized as a serious complication and a potential risk factor for HRA failure in patients undergoing this procedure [15, 16]. Pseudotumors usually develop as solid or fluid masses in the peri-prosthetic soft tissue, as a reaction to metal debris; however, their pathogenesis has not yet been clarified [39]. Interestingly, changes in the head-neck ratio and femoral neck thinning have been associated with pseudotumor formation in patients undergoing metal-on-metal HRA [40]. In our study, two patients (1.38%) showed neck thinning at radiographic examination; however, no ALTR or pseudotumor formation was observed during follow-up. Aseptic loosening of femoral and acetabular components and prosthesis dislocation have also been
described as possible complications of both HRA and THA [1–4, 7–9]. In our study, only one case (0.69%) of aseptic loosening and no dislocations were observed over the 5-year follow-up period, suggesting a low risk of these complications in patients receiving a BHR.

This study must be understood in the context of its limitations. MAINLY, the observational design of the study may predispose to selection bias. Nevertheless, it allows for an evaluation of the prosthesis efficacy under routine clinical conditions, thus adding to the external validity and generalizability of the study results. Another possible limitation may be related to the reduced availability of data regarding long-term prosthesis survival (≥10year) in the study cohort. Despite this, studies from the literature have reported similar long-term survival rates as the one observed in this study [17, 22, 23], thus suggesting that our estimation of BHR 10-year survival may be representative of the intended target population.

Conclusion
Overall, our results indicate that besides showing good implant survival, BHR arthroplasty provides a significant improvement in patients’ functional status and allows a prompt return to both work and physical activities. Based on this, BHR may be regarded as an effective alternative in the treatment of young active patients with hip OA in Spain. Nevertheless, further investigation and perhaps the creation of a national arthroplasty registry may help confirm these findings in the general population.

Abbreviations
ADL: Activities of daily living; ALTR: Adverse local tissue reaction; AVN: Avascular necrosis; BMI: Body mass index; CI: Confidence interval; HHS: Harris hip score; HRA: Hip resurfacing arthroplasty; LOS: Length of stay; MoM: Metal on metal; OA: Osteoarthritis; OHS: Oxford hip score; ROM: Range of motion; SD: Standard deviation; THA: Total hip arthroplasty

Acknowledgements
We would like to thank Ms. Carmen Martínez de la Riva for her assistance with study administration.

Funding
Not applicable.

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions
All authors substantially contributed to the work presented in this paper. OSP-M conceived the study and collected patient data. MEF-C and OSP-M participated in the study coordination. RL-M performed the surgeries and participated in the writing of the manuscript. IN-B, EA-I and MJA-F participated in the writing and revision of the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate
The study was approved by the Clinical Research Ethics Committee of La Princesa University Teaching Hospital and was performed in accordance with the guidelines of the Helsinki Declaration. All participants provided written informed consent preoperatively.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References
1. Liu X-W, Zi Y, Xiang L-B, Wang Y. Total hip arthroplasty: a review of advances, advantages and limitations. Int J Clin Exp Med. 2015;8(27–36.
2. Dorr LD, Kane TJ, Conaty JP. Long-term results of cemented total hip arthroplasty in patients 45 years old or younger. J Arthroplast. 1994;4:453–6.
3. Chamley J. Low friction arthroplasty of the hip. Theory and practice. Berlin: Springer-Verlag Berlin Heidelberg, 1979.
4. Robertson A, Lavallette D, Morgan S, Angus PD. The hydroxyapatite-coated BiPlant hip – outcome in patients under the age of 55 years. J Bone Joint Surg Br. 2005;87B:12–5.
5. Cadossi M, Tedesco G, Sambri A, Mazzotti A, Giannini S. Hip resurfacing implants. Orthopedics. 2015;38:804–9.
6. Marques EMR, Humphris R, Welton NJ, Higgins JPT, Hollingworth W, Lopez-Lopez JA, et al. The choice between hip prosthetic bearing surfaces in total hip replacement: a protocol for a systematic review and network meta-analysis. Syst Rev. 2016;5:19.
7. Freeman MA. Total surface replacement hip arthroplasty. Clin Orthop Relat Res. 1978;134:2–4.
8. Amstutz HC, Clarke IC, Christie J, Graft-Radford A. Total hip articular replacement by internal eccentric shells: the “tharies” approach to total surface replacement arthroplasty. Clin Orthop Relat Res. 1977;128:261–84.
9. Amstutz H, Le Duff M. Background of metal-on-metal resurfacing. Proceedings of the Institution of Mechanical Engineers, Part H: Eng Med. 2006;220:855–94.
10. Sermon R, Balkisson R, Valle C-J. Della. Current indications for hip resurfacing arthroplasty in 2016. Curr Rev Musculoskelet Med. 2016;9:84–92.
11. McMinn D, Treacy R, Lin K, Pynten P. Metal on metal surface replacement of the hip. Experience of the McMinn prosthesis. Clin Orthop Relat Res. 1996;329:S89–98.
12. Tharani R, Dorey FJ, Schmalzried TP, Tharani BR. The risk of cancer following total hip or knee arthroplasty. J Bone Joint Surg Am. 2001;83:774–80.
13. MacDonald SJ. Can a safe level for metal ions in patients with metal-on-metal total hip arthroplasties be determined? J Arthroplast. 2004;19:71–7.
14. Little CP, Ruiz AL, Harding U, McLardy-Smith P, Gundlue M, Murray DW, et al. Osteonecrosis in retrieved femoral heads after failed resurfacing arthroplasty of the hip. J Bone Joint Surg Br. 2005;87:320–3.
15. Pandit H, Glyn-Jones S, McLardy-Smith P, Gundlue R, Whitwell D, Gibbons CLM, et al. Pseudotumours associated with metal-on-metal hip resurfacings. J Bone Joint Surg Br. 2008;90B:847–51.
16. Murray DW, Grammatopoulos G, Gundlue R, Gibbons CLHM, Whitwell D, Taylor A, et al. Hip resurfacing and pseudotumour. Hip Int. 2011;21:279–83.
17. Daniel J, Pynten PB, McMinn DJW. Metal-on-metal resurfacing of the hip in patients under the age of 55 years with osteoarthrosis. J Bone Joint Surg Br. 2004;86:177–84.
18. Anissian HL, Stark A, Gustafson A, Good V, Clarke IC. Metal-on-metal bearing in hip prosthesis generates 100-fold less wear debris than metal-on-polyethylene. Acta Orthop Scand. 1999;70:578–82.
19. Steffen RT, De Smet KA, Murray DW, Gill HS. A modified posterior approach preserves femoral head OXgenation during hip resurfacing. J Arthroplasty Elsevier Inc. 2011;26:404–8.
20. Dawson J, Fitzpatrick R, Frost S, Gundlue R, McLardy-Smith P, Murray D. Evidence for the validity of a patient-based instrument for...
21. Nilssdotter A, Bremander A. Measures of hip function and symptoms. Arthritis Care Res (Hoboken). 2011;63:500–7.
22. Treacy RBC, McBryde CW, Pynsent PB. Birmingham hip resurfacing arthroplasty. A minimum follow-up of five years. J Bone Joint Surg Br. 2005;87:167–70.
23. Murray DW, Grammatopoulos G, Pandit H, Gundle R, Gill HS, McLardy-Smith P. The ten-year survival of the Birmingham hip resurfacing: an independent series. J Bone Joint Surg Br. 2012;94:1180–6.
24. Daniel J, Pradhan C, Ziaee H, Pynsent PB, McMinn DJW. Results of Birmingham hip resurfacing at 12 to 15 years: a single-surgeon series. Bone Joint J. 2014;96-B:1098–306.
25. Sandford N, Muirhead-Allwood SK, Skinner JA. Return to sporting activity after Birmingham hip resurfacing arthroplasty: mid term results. Indian J Orthop. 2015;49:595–601.
26. Mont M, Ragland PS, Etienne G, Seyler TM, Schmalzried TP. Hip resurfacing arthroplasty. J Am Acad Orthop Surg. 2006;14:654–63.
27. Ball ST, Le Duff MJ, Amstutz HC. Early results of conversion of a failed femoral component in hip resurfacing arthroplasty. J Bone Joint Surg Am. 2007;89:335–41.
28. Amstutz HC, Beaule PE, Dorey FJ, Le Duff MJ, Campbell PA, Gruen TA. Metal-on-metal hybrid surface arthroplasty: two to six-year follow-up study. J Bone Joint Surg Am. 2004;86:28–39.
29. Shimmin AJ, Back D. Femoral neck fractures following Birmingham hip resurfacing: a national review of 50 cases. J Bone Joint Surg Br. 2005;87:463–4.
30. Quesada MJ, Markert DR, Mont MA. Metal-on-metal hip resurfacing. J Arthroplast. 2008;23:69–73.
31. Sidler-Maier CC, Waddell JP. Incidence and predisposing factors of periprosthetic proximal femoral fractures: a literature review. Int Orthop. 2015;39:1673–82.
32. Shimmin AJ, Bare J, Back DL. Complications associated with hip resurfacing arthroplasty. Orthop Clin North Am. 2005;36:187–93.
33. Howie DW, Cornish BL, Vernon-Roberts B. The viability of the femoral head after resurfacing hip arthroplasty in humans. Clin Orthop Relat Res. 1993;291:171–84.
34. Campbell P, Mirra J, Amstutz HC. Viability of femoral heads treated with resurfacing arthroplasty. J Arthroplast. 2002;17:20–2.
35. Steffen RT, Smith SR, Urban JG, McLardy-Smith P, Beard DJ, Gill HS, et al. The effect of hip resurfacing on oxygen concentration in the femoral head. J Bone Joint Surg Br. 2005;87:1468–74.
36. Nork SE, Schar M, Pfander G, Beck M, Djonov V, Ganz R, et al. Anatomic considerations for the choice of surgical approach for hip resurfacing arthroplasty. Orthop Clin North Am. 2005;36:163–70.
37. Latham J, Treacy RBC, Shetty VD, Villar RN. To resurface or replace the hip in the under 65-year-old. Ann R Coll Surg Engl. 2006;88:349–53.
38. De Smet KA. Belgium experience with metal-on-metal surface arthroplasty. Orthop Clin North Am. 2005;36:203–13.
39. Pandit H, Whythe M, Whitwell D, Crook D, Luymans R, Oski S, et al. Necrotic granulomatous pseudotumours in bilateral resurfacing hip arthroplasties: evidence for a type IV immune response. Virchows Arch. 2008;453:529–34.
40. Grammatopoulos G, Pandit H, Murray DW, Gill HS, Gill HS. The relationship between head-neck ratio and pseudotumour formation in metal-on-metal resurfacing arthroplasty of the hip. J Bone Joint Surg Br. 2010;92-B:1527–34.